Datavault AI Expands DataMEDS Licensing Agreement Into Commercial Healthcare, Targeting Patient-Controlled Data Models

Datavault AI Inc. (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS) to extend its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The expanded relationship is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.

Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.

The implications of this announcement are significant for the healthcare and blockchain industries. By integrating Datavault AI’s technology into commercial healthcare, the partnership aims to give patients greater control over their health data, allowing them to monetize their own information. This could disrupt traditional healthcare data management models, where patient data is often controlled by providers or third parties. The use of blockchain for real-world asset tokenization also opens new possibilities for securing and verifying medical records, lab results, and wearable device data, potentially reducing fraud and improving data integrity.

Moreover, the expansion into healthspan and wellness applications aligns with the growing focus on preventive care and personalized medicine. The global health and wellness market is expanding rapidly, and the ability to tokenize health data could create new economic incentives for individuals to engage in healthy behaviors. Datavault AI’s technology, which includes AI-driven remote patient monitoring and IoT population health solutions, could enhance the efficiency of healthcare delivery and reduce costs.

For Datavault AI, this deal provides a significant equity stake in DataMEDS and a foothold in the healthcare sector, diversifying its portfolio beyond its core Acoustic Sciences and Data Sciences divisions. The company’s platform, which already serves industries like sports, entertainment, and fintech, now has a path to healthcare applications. The expanded agreement also validates Datavault AI’s technology for secure data monetization and digital twin creation, as highlighted by its Information Data Exchange platform.

Investors should note that this partnership could accelerate revenue growth for both companies, particularly as healthcare data monetization becomes more mainstream. However, regulatory hurdles around patient data privacy and blockchain adoption in healthcare remain challenges. The full press release is available at https://ibn.fm/vBAxH.

Datavault AI Inc. (NASDAQ: DVLT) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions. More information is available at https://dvlt.ai.